FWM
TEVA icon

Focused Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Focused Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,564
Closed -$37.2K – 890
2023
Q4 		$37.2K Sell
3,564
-132
-4% -$1.23K 0.01% 347
2023
Q3 		$37.7K Sell
3,696
-56
-1% -$521 0.01% 330
2023
Q2 		$28.3K Hold
3,752
– – 0.01% 373
2023
Q1 		$33.2K Buy
3,752
+329
+10% +$3.25K 0.01% 365
2022
Q4 		$31.2K Sell
3,423
-735
-18% -$6.41K 0.01% 360
2022
Q3 		$34K Hold
4,158
– – 0.01% 328
2022
Q2 		$31K Hold
4,158
– – 0.01% 342
2022
Q1 		$39K Hold
4,158
– – 0.01% 341
2021
Q4 		$33K Sell
4,158
-1,000
-19% -$9.03K 0.01% 421
2021
Q3 		$50K Sell
5,158
-8,506
-62% -$79.6K 0.01% 383
2021
Q2 		$135K Sell
13,664
-19,903
-59% -$211K 0.02% 248
2021
Q1 		$387K Buy
33,567
+1,268
+4% +$14.5K 0.07% 113
2020
Q4 		$312K Buy
32,299
+2,637
+9% +$25.3K 0.06% 120
2020
Q3 		$267K Sell
29,662
-968
-3% -$10.2K 0.06% 122
2020
Q2 		$378K Buy
30,630
+638
+2% +$7.21K 0.09% 95
2020
Q1 		$269K Buy
29,992
+2,302
+8% +$23.6K 0.08% 101
2019
Q4 		$271K Buy
27,690
+622
+2% +$5.55K 0.06% 115
2019
Q3 		$186K Sell
27,068
-6,367
-19% -$48.8K 0.05% 147
2019
Q2 		$309K Sell
33,435
-7,372
-18% -$88.9K 0.08% 104
2019
Q1 		$640K Sell
40,807
-241
-0.6% -$4.25K 0.19% 71
2018
Q4 		$633K Buy
41,048
+2,494
+6% +$51.1K 0.22% 73
2018
Q3 		$830K Sell
38,554
-1,349
-3% -$31.3K 0.28% 62
2018
Q2 		$970K Buy
39,903
+902
+2% +$18.4K 0.34% 50
2018
Q1 		$667K Buy
39,001
+1,840
+5% +$35.9K 0.21% 72
2017
Q4 		$704K Sell
37,161
-24,136
-39% -$363K 0.23% 66
2017
Q3 		$1.08M Buy
61,297
+19,981
+48% +$450K 0.36% 47
2017
Q2 		$1.37M Buy
41,316
+9,381
+29% +$290K 0.51% 37
2017
Q1 		$1.02M Buy
31,935
+2,590
+9% +$88.4K 0.4% 43
2016
Q4 		$1.06M Buy
29,345
+11,445
+64% +$457K 0.45% 36
2016
Q3 		$824K Buy
17,900
+233
+1% +$12.2K 0.36% 42
2016
Q2 		$887K Sell
17,667
-280
-2% -$14.9K 0.41% 42
2016
Q1 		$960K Sell
17,947
-1,170
-6% -$68.7K 0.52% 40
2015
Q4 		$1.25M Buy
19,117
+687
+4% +$42.5K 0.72% 30
2015
Q3 		$1.04M Buy
18,430
+13
+0.1% +$843 0.66% 36
2015
Q2 		$1.09M Sell
18,417
-852
-4% -$52.6K 0.67% 35
2015
Q1 		$1.2M Sell
19,269
-971
-5% -$56.5K 0.74% 31
2014
Q4 		$1.16M Sell
20,240
-926
-4% -$51.6K 0.82% 28
2014
Q3 		$1.14M Sell
21,166
-1,261
-6% -$66.8K 0.87% 31
2014
Q2 		$1.18M Buy
22,427
+520
+2% +$26.6K 0.92% 29
2014
Q1 		$1.16M Buy
21,907
+10,258
+88% +$474K 0.97% 24
2013
Q4 		$467K Buy
11,649
+5,386
+86% +$212K 0.39% 52
2013
Q3 		$237K Buy
+6,263
New +$244K 0.23% 72

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Focused Wealth Management's TEVA Position: Q1 2024 in Review

Focused Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2024, closing a stake of 3,564 shares — an estimated $37.2K sold.

Focused Wealth Management first reported a position in TEVA in Q3 2013 and held it in 42 quarters. The position peaked at $1.37M in Q2 2017. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Focused Wealth Management reported no remaining Teva Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Focused Wealth Management sold 3,564 Teva Pharmaceuticals shares in Q1 2024, an estimated $37.2K.
  • Focused Wealth Management first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 42 quarters.
  • Focused Wealth Management's Teva Pharmaceuticals position peaked at $1.37M in Q2 2017.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.